Skoumal M, Kolarz G, Klingler A
Institute for Rheumatology of the Kurstadt Baden, Austria.
Scand J Rheumatol. 2003;32(3):156-61. doi: 10.1080/03009740310002498.
To examine whether cartilage oligomeric matrix protein (COMP) correlates with inflammation and/or joint destruction of patients with rheumatoid arthritis (RA) and to test COMP as predicting factor for the outcome of patients with established RA.
Serum levels of COMP were measured in sera of 62 patients, suffering from RA according to the ACR criteria and treated in intervals in our department, over a period of 5 years. A commercially available sandwich--type ELISA-kit developed by AnaMar Medical AB, Sweden, was used. The results of serum COMP were compared with the Disease Activity Score (DAS), the Larsen Score, and clinical and laboratory parameters.
We found a positive correlation between serum levels of COMP at baseline and deterioration of Larsen score even after 5 years (p < 0.007; r = 0.34). To confirm serum COMP as an independent predicting factor for patients with RA we looked at a subgroup of patients (n = 17) with elevated serum levels of COMP (mean 11,7 U/l) and low clinical prognostic factors. In this subgroup we also found a significant correlation with delta Larsen score (p < 0.01; r = 0.59) after 5 years.
Serum levels of COMP is known to reflect increased cartilage turnover. The results indicate that serum COMP may be used as a prognostic marker of cartilage degradation in a patient group with established RA.
研究软骨寡聚基质蛋白（COMP）是否与类风湿关节炎（RA）患者的炎症和/或关节破坏相关，并检验COMP作为已确诊RA患者预后预测指标的价值。
对62例符合美国风湿病学会（ACR）标准且在我院接受了5年间歇性治疗的RA患者的血清进行COMP水平检测。采用瑞典AnaMar Medical AB公司生产的商用夹心型ELISA试剂盒。将血清COMP检测结果与疾病活动评分（DAS）、 Larsen评分以及临床和实验室参数进行比较。
我们发现，即使在5年后，基线时血清COMP水平与Larsen评分恶化之间仍呈正相关（p < 0.007；r = 0.34）。为了确定血清COMP是RA患者的独立预测指标，我们观察了血清COMP水平升高（平均11.7 U/l）且临床预后因素较差的患者亚组（n = 17）。在该亚组中，我们还发现5年后血清COMP水平与Larsen评分变化值之间存在显著相关性（p < 0.01；r = 0.59）。
已知血清COMP水平可反映软骨更新增加。结果表明，血清COMP可作为已确诊RA患者软骨降解的预后标志物。
